Clinical trials: Oligometastatic Prostate Carcinoma
Oligometastasis, Lung Cancer
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients…
- Conditions
- Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
- Trial name
- ID-COMET (NCT06563388)
- Testing
- Stereotactic Ablative Radiotherapy, Best Practice
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
This trial studies how well fluciclovine 18F PET/CT imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug used to measure tumor growth.
- Conditions
- Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
- Trial name
- NCT03707184
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Prostate Cancer, Stereotactic Body Radiation Therapy
START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor…
- Trial name
- START-MET (NCT05209243)
- Testing
- SBRT, STANDARD OF CARE
- Where
- 2 sites in Spain
- Volunteers
- 266 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostatic Neoplasms, Castration-Resistant
Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.
The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant…
- Trial name
- OLIGORESIST (NCT07717268)
- Testing
- Xtandi, Zytiga® (Abiraterone Acetate), SBRT
- Where
- 15 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)
Metastatic castration resistant prostate cancer causes approximately 258400 deaths annually worldwide. In the presence of metastatic disease, systemic treatment remains the main clinical option.
- Trial name
- ARTO (NCT03449719)
- Testing
- SBRT - Ablative radiation Therapy, Abiraterone Acetate
- Volunteers
- 174 people
- Sponsor
- Lorenzo Livi
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC